Specifically, patients with SLC7A5+SLC3A2+ tumours were significantly associated with disease recurrence, distant metastasis and a high risk of death from breast cancer (p < 0.05; Figure 2A–C) compared with the other subgroups, which showed better clinical outcome. This evidence concerns the gene SLC3A2 and neoplasm.